カテゴリ： GlobalData, アメリカ, 企業調査

Acceleron Pharma Inc (XLRN)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Acceleron Pharma Inc (XLRN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9774
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：75
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Acceleron Pharma Inc (Acceleron Pharma) is a clinical stage biopharmaceutical company that discovers, develops and commercializes therapeutics to treat serious and rare diseases. The company’s lead therapeutic candidate, luspatercept, is in phase 3 studyused for the treatment of the myelodysplastic syndromes, beta-thalassemia and myelofibrosis. It also offers pipeline products for the treatment of facioscapulohumeral muscular dystrophy, neuromuscular diseases, renal cell carcinoma and other indications. The company partners with various biopharmaceutical companies and research institutes to advance the development of its lead products. Acceleron Pharma is headquartered in Cambridge, Massachusetts, the US.

Acceleron Pharma Inc (XLRN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Acceleron Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Charcot-Marie-Tooth Association Enters into Co-Development Agreement with Acceleron Pharma 11
Adimab Enters into Agreement with Acceleron Pharma 12
Licensing Agreements 13
Acceleron Pharma Enters into Licensing Agreement with Celgene 13
Acceleron Pharma Enters into Licensing Agreement with Beth Israel Deaconess Medical Center 15
Equity Offering 16
Acceleron Pharma Raises USD230 Million in Public Offering of Shares 16
Acceleron Pharma Raises USD150 Million in Public Offering of Shares 18
Acceleron Pharma Completes Public Offering Of Shares For US$138 Million 20
Acceleron Pharma Completes IPO For US$96.3 Million 22
Acceleron Pharma Completes Private Placement Of Shares For US$10 Million 24
Acceleron Pharma Inc – Key Competitors 26
Acceleron Pharma Inc – Key Employees 27
Acceleron Pharma Inc – Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Recent Developments 29
Financial Announcements 29
Oct 30, 2018: Acceleron reports third quarter 2018 operating and financial results 29
Aug 02, 2018: Acceleron reports second quarter 2018 operating and financial results 31
May 08, 2018: Acceleron Reports First Quarter 2018 Operating and Financial Results 33
Feb 27, 2018: Acceleron Reports Fourth Quarter and Full Year 2017 Operating and Financial Results 35
Aug 03, 2017: Acceleron Pharma Reports Second Quarter 2017 Operational and Financial Results 37
May 08, 2017: Acceleron Pharma Reports First Quarter 2017 Operational and Financial Results 39
Mar 01, 2017: Acceleron Reports Fourth Quarter and Year Ended 2016 Operational and Financial Results 41
Corporate Communications 43
Jul 05, 2018: Acceleron Names Robert K. Zeldin, M.D., Chief Medical Officer 43
Nov 15, 2017: Acceleron Announces Appointment of Dr. Karen Smith to its Board of Directors and Departure of Terrance McGuire 44
May 02, 2017: Acceleron Announces Management Change 45
Product News 46
11/01/2017: Acceleron to Present Sotatercept Clinical Data at 59th American Society of Hematology Annual Meeting and Exposition 46
07/05/2018: Acceleron Appoints Robert K. Zeldin, M.D., Chief Medical Officer 47
02/08/2018: Acceleron Announces Appointment of Chief Commercial Officer 48
Clinical Trials 49
Jul 09, 2018: Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III ‘BELIEVE’ Study in Adults with Transfusion-Dependent Beta-Thalassemia 49
Jun 28, 2018: Celgene and Acceleron Announce Luspatercept Achieved Primary and Key Secondary Endpoints in Phase III ‘MEDALIST’ Study in Patients with Low-to-Intermediate Risk Myelodysplastic Syndromes 50
Jun 15, 2018: Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Beta-Thalassemia at the 23rd Congress of the European Hematology Association 51
Jun 04, 2018: Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Myelodysplastic Syndromes at the ASCO 2018 Annual Meeting 52
May 17, 2018: Acceleron Announces Presentations on Luspatercept at the 23rd Congress of the European Hematology Association 53
Apr 26, 2018: Acceleron Announces Presentations on Lead Product Candidate Luspatercept at the 2018 American Society of Clinical Oncology Annual Meeting 54
Jan 03, 2018: Acceleron Announces Planned Retirement of Chief Medical Officer, Dr. Matthew L. Sherman 55
Dec 10, 2017: Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Myelodysplastic Syndromes at the 59th Annual Meeting of the American Society of Hematology 56
Nov 14, 2017: Acceleron Announces Preclinical Results in Pulmonary Arterial Hypertension at the American Heart Association 2017 Scientific Sessions 58
Nov 01, 2017: Acceleron to Present Clinical Presentations on Investigational Drug Candidate Luspatercept at 59th American Society of Hematology Annual Meeting and Exposition 59
Sep 19, 2017: Acceleron Provides Clinical Update on Luspatercept at 2017 R&D Day 60
Sep 19, 2017: Acceleron Provides Clinical Update on Sotatercept at 2017 R&D Day 61
Sep 19, 2017: Acceleron to Develop Sotatercept in Pulmonary Arterial Hypertension 62
Sep 05, 2017: Acceleron Announces Publication of Luspatercept Phase 2 Myelodysplastic Syndromes Study Results in The Lancet Oncology 63
Jun 23, 2017: Acceleron Provides Updated Results from Ongoing Phase 2 Study of Luspatercept in Myelodysplastic Syndromes at the 22nd Congress of the European Hematology Association 64
Jun 23, 2017: Acceleron Provides Updated Results from Phase 2 Studies of Luspatercept in Beta-Thalassemia at the 22nd Congress of the European Hematology Association 66
Jun 01, 2017: Celgene and Acceleron Complete Target Enrollment in the MEDALIST and BELIEVE Phase 3 Studies of Luspatercept in Myelodysplastic Syndromes and Beta-Thalassemia 68
May 18, 2017: Acceleron Announces Clinical Presentations on Luspatercept at the 22nd Congress of the European Hematology Association 69
May 06, 2017: Luspatercept Phase 2 Data Presented at the 14th International Symposium on Myelodysplastic Syndromes 70
Apr 27, 2017: Acceleron Provides Clinical Development Updates on Luspatercept Program 72
Apr 06, 2017: Acceleron Announces Clinical Presentations on Luspatercept at the 14th International Symposium on Myelodysplastic Syndromes 73
Other Significant Developments 74
Jan 06, 2017: Acceleron Outlines Corporate Goals and Priorities for 2017 74
Appendix 75
Methodology 75
About GlobalData 75
Contact Us 75
Disclaimer 75

List of Tables
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Acceleron Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Acceleron Pharma Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Charcot-Marie-Tooth Association Enters into Co-Development Agreement with Acceleron Pharma 11
Adimab Enters into Agreement with Acceleron Pharma 12
Acceleron Pharma Enters into Licensing Agreement with Celgene 13
Acceleron Pharma Enters into Licensing Agreement with Beth Israel Deaconess Medical Center 15
Acceleron Pharma Raises USD230 Million in Public Offering of Shares 16
Acceleron Pharma Raises USD150 Million in Public Offering of Shares 18
Acceleron Pharma Completes Public Offering Of Shares For US$138 Million 20
Acceleron Pharma Completes IPO For US$96.3 Million 22
Acceleron Pharma Completes Private Placement Of Shares For US$10 Million 24
Acceleron Pharma Inc, Key Competitors 26
Acceleron Pharma Inc, Key Employees 27
Acceleron Pharma Inc, Subsidiaries 28

List of Figures
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Acceleron Pharma Inc (XLRN)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • HollyFrontier Corporation：企業の戦略・SWOT・財務分析
    HollyFrontier Corporation - Strategy, SWOT and Corporate Finance Report Summary HollyFrontier Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Avon Products, Inc.：企業の戦略・SWOT・財務情報
    Avon Products, Inc. - Strategy, SWOT and Corporate Finance Report Summary Avon Products, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Access Bio Inc (950130)：企業の製品パイプライン分析2018
    Summary Access Bio Inc (Access Bio) is a medical device company that research, develops, manufactures and markets in-vitro diagnostics tests, biosensor, and molecular diagnostic products. The company provides in vitro diagnostic technology such as immunochemical, biochemical and molecular products. …
  • Investment Technology Group, Inc.：企業の戦略・SWOT・財務情報
    Investment Technology Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Investment Technology Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Viettel Group：企業の戦略・SWOT・財務情報
    Viettel Group - Strategy, SWOT and Corporate Finance Report Summary Viettel Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Greenhill & Co Inc：企業の戦略・SWOT・財務情報
    Greenhill & Co Inc - Strategy, SWOT and Corporate Finance Report Summary Greenhill & Co Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • ZAPPALLAS, Inc. (3770)：企業の財務・戦略的SWOT分析
    ZAPPALLAS, Inc. (3770) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Nigeria LNG Ltd：企業の戦略的SWOT分析
    Nigeria LNG Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Electra Ltd (ELTR)：企業の財務・戦略的SWOT分析
    Electra Ltd (ELTR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • TOTVS SA：企業の戦略・SWOT・財務分析
    TOTVS SA - Strategy, SWOT and Corporate Finance Report Summary TOTVS SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • The Jean Coutu Group (PJC) Inc.：企業の戦略・SWOT・財務分析
    The Jean Coutu Group (PJC) Inc. - Strategy, SWOT and Corporate Finance Report Summary The Jean Coutu Group (PJC) Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • CSR Ltd：企業の戦略・SWOT・財務情報
    CSR Ltd - Strategy, SWOT and Corporate Finance Report Summary CSR Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • IV Diagnostics Inc-医療機器分野：企業M&A・提携分析
    Summary IV Diagnostics Inc (IV Diagnostics) is a biomedical company that offers research services. The company conducts molecular diagnostic tests for circulating tumor cells and other blood borne diseases. It develops, tests and markets diagnostic tools that monitor and measure cancer tumor cells. …
  • Power Assets Holdings Limited (6)：石油・ガス：M&Aディール及び事業提携情報
    Summary Power Assets Holdings Limited (Power Assets) a subsidiary of CK Infrastructure Holdings Limited, is an investment holding company. The company through its subsidiaries, joint ventures, and affiliates, invests in power and utility-related businesses. The company has interests in electricity g …
  • Broadridge Financial Solutions, Inc.：戦略・SWOT・企業財務分析
    Broadridge Financial Solutions, Inc. - Strategy, SWOT and Corporate Finance Report Summary Broadridge Financial Solutions, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Emami Limited：戦略・SWOT・企業財務分析
    Emami Limited - Strategy, SWOT and Corporate Finance Report Summary Emami Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Sirona Biochem Corp (SBM)：企業の財務・戦略的SWOT分析
    Summary Sirona Biochem Corp (Sirona Biochem) is a biotechnology company that discovers and develops therapeutics, cosmeceuticals and biological ingredients. The company develops drugs for diabetes and cancer. It offers cosmeceutical programs such as development of anti-aging and depigmenting agents, …
  • Tocardo International BV：電力：M&Aディール及び事業提携情報
    Summary Tocardo International BV (Torcado), a subsidiary of Tribute Resources Inc, is an energy equipment provider that manufactures and markets offshore turbines. The company offers wind turbines, sea defences, commercial demonstrator and others. It also offers river and tidal turbines. Torcado’s p …
  • BELECTRIC GmbH：電力：M&Aディール及び事業提携情報
    Summary Belectric GmbH (Belectric) is a renewable energy company that offers solar systems and solutions. The company manufactures, designs, and constructs photovoltaic rooftop installation systems for solar-projects and ground-mounted solar power plants. It manufactures BoS components, photovoltaic …
  • City Developments Ltd：企業の戦略・SWOT・財務分析
    City Developments Ltd - Strategy, SWOT and Corporate Finance Report Summary City Developments Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆